Cyclotide Scaffolds Enable Orally Active Peptide Drugs Targeting GPCRs
Plant-derived cyclotides serve as ultra-stable scaffolds that can be engineered to carry bioactive sequences, creating orally active peptide drugs targeting G protein-coupled receptors.
Quick Facts
What This Study Found
Molecular grafting of bioactive epitopes into cyclotide scaffolds produces GPCR ligands with improved oral activity, enzymatic stability, and selectivity compared to linear peptide counterparts.
Key Numbers
GPCRs: ~34% of approved drug targets; cyclotides: cyclic cystine knot, 3 disulfide bonds; some show oral activity in vivo
How They Did This
Review of molecular grafting approaches using cyclotide scaffolds to engineer novel GPCR-targeting peptide ligands, with examples of improved pharmacokinetics.
Why This Research Matters
Peptide drugs typically cannot be taken orally and degrade quickly. Cyclotide scaffolds solve both problems, potentially enabling a new generation of oral peptide medicines targeting the largest class of drug targets.
The Bigger Picture
Cyclotides bridge the gap between small molecules (orally available but limited) and biologics (potent but injectable), creating a hybrid approach to drug design with the best of both worlds.
What This Study Doesn't Tell Us
Review — most examples are preclinical; oral bioavailability improvements vary by construct; manufacturing scalability of cyclotide-based drugs not fully addressed.
Questions This Raises
- ?Which GPCR targets are most amenable to cyclotide-based drug design?
- ?Can cyclotide scaffolds accommodate larger bioactive sequences without losing stability?
- ?How do manufacturing costs of cyclotide drugs compare to conventional peptide therapeutics?
Trust & Context
- Key Stat:
- Oral peptide activity achieved Cyclotide scaffolds confer oral bioavailability and enzymatic stability to grafted bioactive peptide sequences
- Evidence Grade:
- Well-supported review with concrete examples of successful grafting approaches, but most applications remain preclinical.
- Study Age:
- Published in 2020; cyclotide engineering has continued to advance with new GPCR targets and improved grafting strategies.
- Original Title:
- Harnessing cyclotides to design and develop novel peptide GPCR ligands.
- Published In:
- RSC chemical biology, 1(4), 177-191 (2020)
- Authors:
- Muratspahić, Edin(2), Koehbach, Johannes(2), Gruber, Christian W(2), Craik, David J
- Database ID:
- RPEP-05017
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are cyclotides?
Naturally occurring cyclic peptides from plants with an ultra-stable structure called a cyclic cystine knot, making them resistant to heat, enzymes, and stomach acid.
Can peptide drugs be taken orally?
Most cannot, but cyclotide scaffolds protect grafted peptide sequences from digestive degradation, enabling oral bioavailability — a major advance in peptide drug design.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05017APA
Muratspahić, Edin; Koehbach, Johannes; Gruber, Christian W; Craik, David J. (2020). Harnessing cyclotides to design and develop novel peptide GPCR ligands.. RSC chemical biology, 1(4), 177-191. https://doi.org/10.1039/d0cb00062k
MLA
Muratspahić, Edin, et al. "Harnessing cyclotides to design and develop novel peptide GPCR ligands.." RSC chemical biology, 2020. https://doi.org/10.1039/d0cb00062k
RethinkPeptides
RethinkPeptides Research Database. "Harnessing cyclotides to design and develop novel peptide GP..." RPEP-05017. Retrieved from https://rethinkpeptides.com/research/muratspahic-2020-harnessing-cyclotides-to-design
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.